Jazz Pharmaceuticals (NASDAQ: JAZZ) revenue
Jazz Pharmaceuticals reported revenue of $4,268m for fiscal 2025, 4.9% more than in fiscal 2024 ($4,069m). Since fiscal 2016 its revenue has grown by 186.8%, an average growth of 12.4% a year.
Jazz Pharmaceuticals has grown its revenue for 9 years in a row, and fiscal 2025 is the highest of its 10 fiscal years on record.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $4,268m | +4.9% | −$430.2m | −10.1% |
| 2024 | $4,069m | +6.1% | $716.6m | 17.6% |
| 2023 | $3,834m | +4.8% | $578.6m | 15.1% |
| 2022 | $3,659m | +18.3% | −$65.5m | −1.8% |
| 2021 | $3,094m | +30.9% | $170.3m | 5.5% |
| 2020 | $2,364m | +9.3% | $378.1m | 16.0% |
| 2019 | $2,162m | +14.3% | $532.4m | 24.6% |
| 2018 | $1,891m | +16.8% | $614.8m | 32.5% |
| 2017 | $1,619m | +8.8% | $528.8m | 32.7% |
| 2016 | $1,488m | — | $591.7m | 39.8% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Jazz Pharmaceuticals revenue compared with its sector
By revenue for its latest fiscal year, Jazz Pharmaceuticals ranks 68th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Jazz Pharmaceuticals, 4.9%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 66th | Illumina | $4,343m | −0.7% |
| 67th | IDEXX Laboratories | $4,304m | 10.4% |
| 68th | Jazz Pharmaceuticals | $4,268m | 4.9% |
| 69th | Perrigo | $4,253m | −2.8% |
| 70th | Cooper Companies | $4,092m | 5.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Jazz Pharmaceuticals
- How much revenue did Jazz Pharmaceuticals make in fiscal 2025?
- Jazz Pharmaceuticals reported revenue of $4,268m for fiscal 2025, compared with $4,069m in fiscal 2024.
- How much has the revenue of Jazz Pharmaceuticals grown?
- Between fiscal 2016 and fiscal 2025 it went from $1,488m to $4,268m: 186.8% more, an average growth of 12.4% a year.
- What was the best year for revenue at Jazz Pharmaceuticals?
- Of its last 10 fiscal years, fiscal 2025, with $4,268m.
- Where does Jazz Pharmaceuticals rank in its sector by revenue?
- It ranks 68th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Jazz Pharmaceuticals come from?
- From the annual report (Form 10-K) that Jazz Pharmaceuticals files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Jazz Pharmaceuticals files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Jazz Pharmaceuticals: the Jazz Pharmaceuticals page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.